Puma Biotechnology Announces Publication of Abstracts for the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Puma Biotechnology (PBYI) Sell-Off on ASCO Abstract 'May be Overdone', Stifel Says
May 14, 2015 6:26 AM EDTStifel analyst Thomas Shrader weighed in on Puma Biotechnology (NYSE: PBYI) after the 20% sell-off in the stock following the ASCO abstract. He said the reaction in the stock may be overdone.
"An unexpectedly strong showing by the control arm in Pumas ExteNet trial left neratinib little room to improve on SOC," Shrader commented. "Its still a positive trial to our eyes, but the risk benefit for... More
Puma Biotech (PBYI) Reports Publication of Abstracts for ASCO
May 13, 2015 5:16 PM EDTPuma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the release of four abstracts on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be... More
